This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on Web of Science (4)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Monica M. Stringfellow, MD; Richard E. Wilson, MD; Steven J. Burakoff, MD; Steven H. Herrmann, MD

Arch Surg. 1989;124(1):81-84.

Abstract
• Encouraging results of clinical trials with interleukin 2 therapy for advanced malignant neoplasms have led to efforts to reduce the toxicity and improve the efficacy of tumor immunotherapy. To begin to achieve this goal, we studied the lymphokine requirements for in vitro generation of polyclonal cytotoxic T lymphocytes (CTL) from C57BL/6 murine thymocytes. We found that both interleukin 2 and interleukin 6 are required for optimal generation of CTL from murine thymocytes. Timing studies show that neither lymphokine alone in culture will produce maximum CTL levels during the first 84 hours of culture. In addition, we found that thymocytes cultured with concanavalin A are unresponsive unless either interleukin 2 or interleukin 6 is present from the onset of culture.

(Arch Surg 1989;124:81-84)

Author Affiliations
From the Department of Surgery, Brigham and Women's Hospital and Harvard Medical School (Drs Stringfellow and Wilson), and the Departments of Pediatrics and Pathology, Division of Pediatric Oncology, Dana Farber Cancer Institute and Harvard Medical School (Drs Burakoff and Herrmann), Boston.

Footnotes
Accepted for publication Sept 21, 1988.

Read before the Annual Meeting of the Society of Surgical Oncology, New Orleans, May 23, 1988.

Reprint requests to Department of Surgery, Brigham and Women's Hospital, 75 Francis St, Boston, MA 02115 (Dr Stringfellow).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?